Successfully obtained FDA IND acceptance for NBI-1117567, advancing its Alzheimer's cognition program to Phase 2. This regulatory approval demonstrates progress in developing treatments for significant unmet medical needs and strengthens its muscarinic receptor agonist portfolio.
Neurocrine successfully initiated a Phase 2 trial for NBI-1117570, marking the second NxWave-designed compound in their muscarinic agonist portfolio to advance to Phase 2. This demonstrates progress in their schizophrenia treatment program and validates their partnership strategy.
While the acquisition is strategically sound and adds a high-growth product with strong revenue generation ($190M in 2025), the stock declined 2.74% in premarket trading. Technical analysis shows bearish long-term signals (trading 4.5% below 200-day SMA), though the company has a solid 12-month return of 41.13% and strong growth profile.
Stock declined 10.64% following disappointing Ingrezza guidance for 2026 ($2.70-2.80B) and declining Crenessity NRx growth quarter-over-quarter without 2026 product guidance. While analysts remain bullish long-term, near-term sentiment is negative due to the sharp sell-off and light clinical catalysts expected in 2026.
Articles that tag NBIX but are mainly about other companies.
Initiated Phase 2 clinical study of NBI-1117570 for schizophrenia and received US$22.5 million milestone payment from Nxera. Multiple programs in muscarinic receptor agonist portfolio advancing with Phase 3 studies ongoing.
Added to portfolio, indicating healthcare sector positioning aligned with fund themes
Advanced muscarinic agonist portfolio with multiple ongoing Phase 2/3 studies, achieved milestone triggering US$22.5 million payment to Nxera, and initiated Phase 2 trial for NBI-1117570 in schizophrenia.
Stock showed minimal movement (+0.62%) despite the acquisition announcement. While the deal supports portfolio diversification and revenue growth strategy, the market reaction was muted, suggesting neutral sentiment on the acquisition's immediate impact.
Mentioned as a top holding in Sarissa's portfolio (19.3% of AUM) but no specific news or developments discussed in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
